Mamas Mamas speaks with John Davies and J. Dawn Abbott about outcomes when treating patients with chronic total occlusions with PCI.

While the noninvasive methods used different technologies to calculate flow, both were noninferior to the gold standard.

The trial enrolled just half of its planned patients, leaving spironolactone’s role in HFpEF and HFmrEF still up in the air.

In carefully selected patients with CTOs, symptom-driven PCI does provide a benefit when done by experienced operators.

The results challenge the rapid growth of Impella support during high-risk PCI. Investigators say a reckoning is needed.

Investigators suggest LDL targets typically reserved for secondary prevention are best in high-risk patients with diabetes.

The program didn’t have a big impact on BP, but there were lessons for future attempts to address these health disparities.

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

The trial findings complement the updated US dyslipidemia guidelines that promote early and intensive LDL lowering.

Patients with acute intermediate-risk pulmonary embolism (PE) have better short-term outcomes with ultrasound-facilitated, catheter-directed fibrinolysis plus heparin-based anticoagulation compared ...

Tonlamarsen “suppresses hepatic angiotensinogen production,” Laffin told the media ahead of the late-breaking session. “We know that AGT suppression reduces blood pressure among patients taking zero ...